NBSE vs. INM, LSDI, PBLA, ATNF, BDRX, GRI, PRFX, ALLR, QLGN, and PXMD
Should you be buying NeuBase Therapeutics stock or one of its competitors? The main competitors of NeuBase Therapeutics include InMed Pharmaceuticals (INM), Lucy Scientific Discovery (LSDI), Panbela Therapeutics (PBLA), 180 Life Sciences (ATNF), Biodexa Pharmaceuticals (BDRX), GRI Bio (GRI), PainReform (PRFX), Allarity Therapeutics (ALLR), Qualigen Therapeutics (QLGN), and PaxMedica (PXMD). These companies are all part of the "pharmaceutical preparations" industry.
NeuBase Therapeutics (NASDAQ:NBSE) and InMed Pharmaceuticals (NASDAQ:INM) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, community ranking, valuation, analyst recommendations, media sentiment, dividends, profitability and risk.
NeuBase Therapeutics has higher earnings, but lower revenue than InMed Pharmaceuticals.
In the previous week, NeuBase Therapeutics had 1 more articles in the media than InMed Pharmaceuticals. MarketBeat recorded 4 mentions for NeuBase Therapeutics and 3 mentions for InMed Pharmaceuticals. NeuBase Therapeutics' average media sentiment score of 0.97 beat InMed Pharmaceuticals' score of -0.10 indicating that NeuBase Therapeutics is being referred to more favorably in the media.
NeuBase Therapeutics has a net margin of 0.00% compared to InMed Pharmaceuticals' net margin of -115.76%. InMed Pharmaceuticals' return on equity of -54.31% beat NeuBase Therapeutics' return on equity.
NeuBase Therapeutics received 41 more outperform votes than InMed Pharmaceuticals when rated by MarketBeat users. Likewise, 60.49% of users gave NeuBase Therapeutics an outperform vote while only 47.06% of users gave InMed Pharmaceuticals an outperform vote.
NeuBase Therapeutics has a beta of 0.81, meaning that its share price is 19% less volatile than the S&P 500. Comparatively, InMed Pharmaceuticals has a beta of 0.2, meaning that its share price is 80% less volatile than the S&P 500.
12.4% of NeuBase Therapeutics shares are held by institutional investors. Comparatively, 20.1% of InMed Pharmaceuticals shares are held by institutional investors. 7.9% of NeuBase Therapeutics shares are held by insiders. Comparatively, 1.4% of InMed Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Summary
NeuBase Therapeutics beats InMed Pharmaceuticals on 8 of the 12 factors compared between the two stocks.
Get NeuBase Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for NBSE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NBSE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
NeuBase Therapeutics Competitors List
Related Companies and Tools
